Smile Factory Pediatric Dentistry P.l.l.c Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 2483 2nd St Ste D, Eagle Pass, TX 78852 Phone: 830-757-9700 Fax: 830-757-9701 |
Ruben Barron D.d.s, P.c. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1975 N Veterans Blvd, Suite 4, Eagle Pass, TX 78852 Phone: 830-773-8528 Fax: 830-773-8711 |
America Dental Clinic Llc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 269 N Ceylon St, Eagle Pass, TX 78852 Phone: 830-752-0686 Fax: 866-211-8139 |
Kool Smiles Dentist - Endodontics Medicare: Not Enrolled in Medicare Practice Location: 432 S Bibb Ave, Eagle Pass, TX 78852 Phone: 770-916-9000 |
Hector Alvarez D.d.s.,p.a. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1606 E Garrison St, Eagle Pass, TX 78852 Phone: 830-757-1500 |
Family Dental Care Dentist Medicare: Not Enrolled in Medicare Practice Location: 2230 Veterans Blvd Suite 200, Eagle Pass, TX 78852 Phone: 830-773-0707 Fax: 830-757-4550 |
News Archive
The antibody works against the gastric hormone ghrelin (pronounced "grell-in"), which has been linked to weight gain and fat storage through its metabolic actions. These findings point towards a potentially novel treatment for obesity that would interfere directly with the some of the biological mechanisms determining weight.
Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.
The perception that UK backpackers do a lot of drinking while they are travelling across Australia has been supported by new research. Forty per cent reported drinking five or more times a week when in Australia, compared to only just over 20% when they were at home.
Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.
› Verified 9 days ago